PCSK9 and diabetes mellitus: Major trials, such as FOURIER and ODYSSEY OUTCOMES, have demonstrated that PCSK9 inhibitors, like evolocumab and alirocumab, provide additional reductions in LDL-C levels and CV risks, particularly benefiting high-risk populations, including those with diabetes and PAD.